Central and peripheral antinociceptive effects of ellagic acid in different animal models of pain
2013
Taghi Mansouri, Mohammad | Naghizadeh, Bahareh | Ghorbanzadeh, Behnam | Farbood, Yaghoub
The present study was conducted to evaluate the analgesic effects of p.o., i.p., or i.c.v. administration of ellagic acid (EA), and investigate the possible mechanisms underlying the systemic antinociceptive activities in different animal models of pain. Using radiant heat tail-flick test, EA (100–1000μmol/kg, retain-->p.o.) only resulted in antinociception at 1000μmol/kg. Also, EA (10–660μmol/kg, i.p.) produced the antinociceptive effect in a dose-dependent manner with an ED₅₀ of 122μmol/kg. In addition, the i.c.v. administration of EA (0.1–2μmol/rat) resulted in dose-dependent antinociception with an ED₅₀ of 0.33μmol/rat. EA induced antinociception (330μmol/kg. i.p.) was reversed by naloxone (1mg/kg, i.p.). Likewise, EA (1–33μmol/kg, i.p.) produced significant dose-dependent antinociception when assessed using acetic acid-induced abdominal writhing test with an ED₅₀ of 3.5μmol/kg. It was also demonstrated that pre-treatment with l-arginine (100mg/kg, i.p.), a nitric oxide (NO) precursor, and methylene blue (20mg/kg, i.p.), a guanylate cyclase (GC) inhibitor, significantly enhanced antinociception produced by EA suggesting the involvement of l-arginine–NO–cGMP pathway. Additionally, administration of glibenclamide (10mg/kg, i.p.), an ATP-sensitive K⁺ channel blocker, significantly reversed antinociceptive activity induced by EA. Moreover, EA treatment had no effect on the motor activity of rats when tested in rota-rod task. The present results indicate that the dose-related antinociceptive action of EA has both peripheral and central components which involve mediation by opioidergic system and l-arginine–NO–cGMP–ATP sensitive K⁺ channels pathway.
显示更多 [+] 显示较少 [-]